GSK

GSK’s Risvutatug Rezetecan Wins Japan ODD – B7-H3 ADC Targets Small-Cell Lung Cancer with Phase 1 Durable Responses

GlaxoSmithKline (GSK; NYSE: GSK) announced that risvutatug rezetecan (Ris-Rez), a B7-H3-targeted antibody-drug conjugate (ADC), received...

Others

Luzhu Biotechnology Reports 2025 Results – LZ901 Shingles Vaccine Nears Commercialization with Shingrix‑Beating Data

Fineline Cube Mar 20, 2026

Luzhu Biotechnology (HKG: 2480) announced its audited 2025 annual results, highlighting significant progress toward LZ901...

Company Drug

GSK’s Arexvy Wins FDA Label Expansion – RSV Vaccine Now Covers High-Risk Adults Aged 18-49

Fineline Cube Mar 16, 2026

GlaxoSmithKline (GSK, NYSE: GSK) announced FDA approval for a label expansion of its adjuvanted respiratory...

Company Drug

FDA Approves GSK’s Wellcovorin for Cerebral Folate Deficiency – First Treatment for Rare FOLR1 Genetic Disorder

Fineline Cube Mar 11, 2026

The U.S. Food and Drug Administration (FDA) approved expanded use of GlaxoSmithKline’s (GSK, NYSE: GSK)...

Company Deals

GSK Licenses Linerixibat to Alfasigma for $300 Million Upfront – IBAT Inhibitor Targets PBC Pruritus with $690 Million Total Deal Value

Fineline Cube Mar 10, 2026

GlaxoSmithKline (GSK, NYSE: GSK) and Alfasigma S.p.A. announced a licensing agreement granting Alfasigma exclusive global rights...

Company Deals

GSK to Acquire 35Pharma for $950M – Adds Potential Best‑in‑Class PAH Asset HS235

Fineline Cube Feb 26, 2026

GlaxoSmithKline (GSK, NYSE: GSK) announced a definitive agreement to acquire 35Pharma Inc., a Canada‑based clinical‑stage biopharmaceutical...

Company Deals

Frontier Biotech Licenses Two siRNA Assets to GSK in $1B+ Deal – Expands Global RNAi Partnership

Fineline Cube Feb 24, 2026

Frontier Biotechnologies Inc. (SHA: 688221) announced a licensing agreement with GlaxoSmithKline (GSK, NYSE: GSK), granting the UK...

Company

GSK Reports 7% Revenue Growth to $44.7 Billion in 2025; Oncology Surges 43%

Fineline Cube Feb 13, 2026

GlaxoSmithKline plc (GSK, NYSE: GSK) delivered strong 2025 financial results, with total revenues rising 7% in...

Company Drug

GSK’s RSV Vaccine Filing Accepted by NMPA for China Market Entry

Fineline Cube Feb 11, 2026

GlaxoSmithKline plc (GSK, NYSE: GSK) announced that the Center for Drug Evaluation (CDE) of China’s NMPA...

Company Deals

GSK Acquires RAPT Therapeutics for $2.2 Billion, Adding Ozureprubart for Food Allergy Protection

Fineline Cube Jan 22, 2026

GlaxoSmithKline plc (GSK, NYSE: GSK) announced a definitive agreement to acquire RAPT Therapeutics (NASDAQ: RAPT) for USD 58.00...

Company Deals Drug

Alteogen Licenses ALT‑B4 Hyaluronidase to Tesaro for $285M Subcutaneous Dostarlimab Deal

Fineline Cube Jan 22, 2026

Alteogen Inc. (KOSDAQ: 196170) announced an exclusive license agreement with Tesaro, a GSK subsidiary, granting worldwide...

Company Deals

Noetik Enters $50M AI Collaboration with GSK, Licensing OCTO‑VC Virtual Cell Models for NSCLC and CRC

Fineline Cube Jan 12, 2026

Noetik, an AI‑native biotech pioneering self‑supervised machine learning in cancer therapeutics, announced a five‑year strategic...

Company Drug

GSK’s Nucala Wins China Approval as First IL‑5 Biologic for COPD

Fineline Cube Dec 22, 2025

GlaxoSmithKline (GSK, NYSE: GSK) China announced that China’s National Medical Products Administration (NMPA) approved Nucala...

Company Drug

GSK’s Exdensur Wins FDA Approval as First Twice‑Yearly Asthma Biologic

Fineline Cube Dec 17, 2025

GlaxoSmithKline plc (GSK, NYSE: GSK) announced that the U.S. Food and Drug Administration (FDA) approved...

Company Drug

GSK’s Nucala Wins CHMP Nod for COPD in Europe

Fineline Cube Dec 15, 2025

UK biopharma GlaxoSmithKline plc (GSK, NYSE: GSK) announced that the European Medicines Agency’s Committee for...

Company Deals

GSK Terminates Ideaya Synthetic Lethality Partnership, Returns Two Clinical Programs

Fineline Cube Dec 13, 2025

UK biopharma GlaxoSmithKline plc (GSK, NYSE: GSK) has initiated a breakup with Ideaya Biosciences (NASDAQ:...

Company Deals

OBT and GSK Forge Multi-Target Cancer Collaboration Using OGAP Platform

Fineline Cube Dec 13, 2025

Oxford BioTherapeutics (OBT), a clinical‑stage oncology company, announced a multi‑year, multi‑target strategic collaboration with GSK...

Company Drug

Duality DB-1324 ADC FDA IND Approval Advances GSK Partnership

Fineline Cube Dec 4, 2025

Duality Biotherapeutics, Inc. (HKG: 9606) announced that its Investigational New Drug (IND) application for DB-1324,...

Company

GSK Reports Strong Q3 2025 Results, Beats Forecasts with 8% Revenue Growth

Fineline Cube Oct 29, 2025

UK biopharma GlaxoSmithKline plc (GSK, NYSE: GSK) delivered a compelling Q3 2025 earnings report that...

Company Deals

GSK Secures Worldwide Exclusive Rights to Empirico’s EMP‑012, a First‑in‑Class siRNA for COPD

Fineline Cube Oct 29, 2025

GlaxoSmithKline plc (GSK, NYSE: GSK) and Empirico Ltd. today announced a global exclusive licence agreement...

GSK

GSK’s Risvutatug Rezetecan Wins Japan ODD – B7-H3 ADC Targets Small-Cell Lung Cancer with Phase 1 Durable Responses

Luzhu Biotechnology Reports 2025 Results – LZ901 Shingles Vaccine Nears Commercialization with Shingrix‑Beating Data

GSK’s Arexvy Wins FDA Label Expansion – RSV Vaccine Now Covers High-Risk Adults Aged 18-49

FDA Approves GSK’s Wellcovorin for Cerebral Folate Deficiency – First Treatment for Rare FOLR1 Genetic Disorder

GSK Licenses Linerixibat to Alfasigma for $300 Million Upfront – IBAT Inhibitor Targets PBC Pruritus with $690 Million Total Deal Value

GSK to Acquire 35Pharma for $950M – Adds Potential Best‑in‑Class PAH Asset HS235

Frontier Biotech Licenses Two siRNA Assets to GSK in $1B+ Deal – Expands Global RNAi Partnership

GSK Reports 7% Revenue Growth to $44.7 Billion in 2025; Oncology Surges 43%

GSK’s RSV Vaccine Filing Accepted by NMPA for China Market Entry

GSK Acquires RAPT Therapeutics for $2.2 Billion, Adding Ozureprubart for Food Allergy Protection

Alteogen Licenses ALT‑B4 Hyaluronidase to Tesaro for $285M Subcutaneous Dostarlimab Deal

Noetik Enters $50M AI Collaboration with GSK, Licensing OCTO‑VC Virtual Cell Models for NSCLC and CRC

GSK’s Nucala Wins China Approval as First IL‑5 Biologic for COPD

GSK’s Exdensur Wins FDA Approval as First Twice‑Yearly Asthma Biologic

GSK’s Nucala Wins CHMP Nod for COPD in Europe

GSK Terminates Ideaya Synthetic Lethality Partnership, Returns Two Clinical Programs

OBT and GSK Forge Multi-Target Cancer Collaboration Using OGAP Platform

Duality DB-1324 ADC FDA IND Approval Advances GSK Partnership

GSK Reports Strong Q3 2025 Results, Beats Forecasts with 8% Revenue Growth

GSK Secures Worldwide Exclusive Rights to Empirico’s EMP‑012, a First‑in‑Class siRNA for COPD

You Missed

Lilly’s Acquisition of Innovent Biologics Wins FTC Approval – $3+ Billion Deal Clears Key Regulatory Hurdle

Alphamab Oncology Doses First Patient in Phase III KN026 Study – Bispecific HER2 Antibody Targets Adjuvant Breast Cancer

Gilead to Acquire Ouro Medicines for $2.175 Billion – Keymed Biosciences Secures $320 Million from CM336 TCE Deal

Shenzhen Salubris Wins NMPA Approval for SAL0150 – Oral Long-Acting Diabetes/Obesity Drug Targets Weekly Dosing Regimen